Skip to main content
argenx SE logo

argenx SE — Investor Relations & Filings

Ticker · 1AE ISIN · NL0010832176 LEI · 7245009C5FZE6G9ODQ71 BR Manufacturing
Open in API
Filings indexed 667 across all filing types
Latest filing 2026-05-11 Regulatory Filings
Country NL Netherlands
Listing BR 1AE

About argenx SE

https://www.argenx.com/?allow=1

argenx SE is a global immunology company that develops and commercializes antibody-based therapies for severe autoimmune diseases. Its lead product, efgartigimod, is a neonatal Fc receptor (FcRn) antagonist designed to reduce pathogenic Immunoglobulin G (IgG) antibodies. Efgartigimod is marketed as VYVGART and VYVGART Hytrulo for approved indications including generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The company is investigating efgartigimod for several other autoimmune conditions. Its pipeline also includes other first-in-class candidates, such as empasiprubart, a C2 inhibitor for IgM-driven autoimmune diseases. argenx operates an antibody innovation platform, collaborating with academic partners to translate immunology research into therapeutic candidates.

Recent filings

Filing Released Lang Actions
argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
Regulatory Filings Classification · 85% confidence The document is a corporate press release announcing FDA approval of a product label expansion. It contains no financial statements or investor call transcript, nor is it a formal regulatory submission or detailed report. It is an external announcement of approval (“inside information” under EU MAR) and does not fit other categories (e.g., earnings release, capital update, proxy statement). This aligns with the fallback “Regulatory Filings” category for miscellaneous regulatory announcements (RNS).
2026-05-11 English
argenx Reports First Quarter 2026 Financial Results and Provides Business Update
Interim / Quarterly Report Classification · 100% confidence The document is a detailed announcement of the first quarter 2026 financial results of argenx, including comprehensive financial data such as product net sales, operating income, expenses, profit, and earnings per share. It also provides a business update, pipeline progress, management changes, and future financial calendar dates. The presence of unaudited condensed consolidated interim financial statements and substantive financial analysis for a quarter indicates this is a quarterly financial report. The document is lengthy (15,000 characters) and contains actual financial data, not just an announcement or summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2026-05-08 English
6-K - ARGENX SE (0001697862) (Filer)
Regulatory Filings
2026-05-07 English
argenx Announces Results of Annual General Meeting and Board of Directors’ Appointment of Karen Massey as Chief Executive Officer
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document announces the results of the Annual General Meeting (AGM) of shareholders, including voting outcomes and appointments to the Board of Directors. It also details the appointment of a new CEO and Chairperson of the Board. The content focuses on the AGM results and board changes rather than providing the full annual report or financial statements. The document length is under 5,000 characters and primarily serves as an announcement of AGM outcomes and management changes. Therefore, it fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-07 English
argenx to Present at BofA Securities 2026 Health Care Conference
Investor Presentation Classification · 95% confidence The document is a short announcement about argenx's CEO presenting at the BofA Securities 2026 Health Care Conference. It includes details about the presentation date, webcast availability, and company background. There is no financial data, no detailed report, no voting results, no management changes, no legal or regulatory filings, and no mention of any report being attached or published. The document is essentially an investor presentation announcement or event notice. Given the content and length (1502 characters), it fits best as an Investor Presentation (IP) type, as it announces a presentation focused on company strategy and market position.
2026-05-07 English
argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026
Regulatory Filings Classification · 95% confidence The document is a short announcement stating that argenx will report its first quarter 2026 financial results and provide a business update on May 7, 2026. It includes details about a conference call and webcast but does not contain any actual financial data or detailed financial statements. The document length is 1841 characters, which is quite short and fits the pattern of a report publication announcement or earnings release announcement rather than the report itself. Since it announces the upcoming release of quarterly financial results and a business update, it aligns best with an Earnings Release (ER) announcement. However, because it does not contain the actual financial results but only the announcement of the event to discuss them, it is more appropriate to classify it as a Regulatory Filing (RNS) as a general regulatory announcement about the earnings call. The document does not contain the transcript or the financial data itself, so it is not a Call Transcript (CT) or Interim Report (IR). Therefore, the best classification is Regulatory Filings (RNS) with high confidence.
2026-04-30 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.